CME in Minutes: Education in Ophthalmology

Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist's partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians' and patients' perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/FZX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the diagnosis and treatment of diabetic macular edema (DME), including the role of shared decision-making, with a patient's perspective. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy among patients with DME.

Please visit answersincme.com/HEQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses how to optimize the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) using a case-based approach with perspectives from a patient. Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-VEGF therapies used in the treatment of nAMD; Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD; and Explain the importance of shared decision-making in the management of nAMD.

Please visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.

Please visit answersincme.com/YYB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for selecting anti-VEGF therapy and maintaining adherence for patients with diabetic macular edema. Upon completion of this activity, participants should be better able to: Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with diabetic macular edema (DME); Review the clinical profiles of longer-acting vascular endothelial growth factor (VEGF)-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy.

Please visit answersincme.com/MUP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the importance of early detection and referral of patients with retinal vein occlusion (RVO), as well as a personalized and multidisciplinary approach to management. Upon completion of this activity, participants should be better able to: Recognize the rationale for early detection of RVO; Describe the appropriate processes for timely referral of patients with RVO; and Outline strategies for personalized, multidisciplinary management of patients with RVO.

Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.

Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.

Please visit answersincme.com/EUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses new treatments for patients with presbyopia. Upon completion of this activity, participants should be better able to:Recognize the unmet therapeutic needs with available presbyopia treatments; Describe the evidence for late-stage emerging miotic agents being developed to treat presbyopia; and Outline strategies to individualize treatment selection for patients with presbyopia.

Please visit answersincme.com/JZM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal vein occlusion (RVO) discusses selecting among and incorporating anti-vascular endothelial growth factor (VEGF) therapy into treatment plans for patients with macular edema (ME) secondary to RVO. Upon completion of this activity, participants should be better able to: Evaluate the benefit-risk profiles of available anti-VEGF treatments for patients with macular edema secondary to RVO; Discuss practical approaches to optimally incorporate anti-VEGF agents into treatment plans for patients with RVO; and Apply strategies to counsel patients on the use of anti-VEGF agents for RVO to optimize patient outcomes.

Please visit answersincme.com/MYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses best practices in diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize best practices to optimize the prompt and accurate diagnosis of diabetic retinopathy (DR) and diabetic macular edema (DME); and Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME.

Please visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.

Please visit answersincme.com/YCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses anti-VEGF treatment of diabetic retinopathy with or without diabetic macular edema. Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

Please visit answersincme.com/AXS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Adam S. Wenick, an expert in ophthalmology, discusses treatment adherence in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal vascular endothelial growth factor– (VEGF-) targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Review patient counseling approaches to improve treatment adherence to intravitreal VEGF-targeted therapies for nAMD.